FDA's official blog brought to you from FDA's senior leadership and staff stationed at home and abroad – sharing news, background, announcements and other information about the work done at the FDA on behalf of the American public.
By Richard Pazdur, M.D. and Gideon Blumenthal, M.D.
Last week, we approved a new drug for patients with a certain type of late stage, non-small cell lung cancer (NSCLC).
It's one of four targeted therapies for lung cancer that have been approved since 2011—therapies that are the result of a new and forward-thinking approach to understanding the disease and its causes.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1kMekTT
Cap comentari:
Publica un comentari a l'entrada